Percutaneous coronary Interventions in 2023 Challenges & Chances

Prof. Florim Cuculi

Head of Cardiology

Heart Centre Lucerne - Switzerland






Current challenges in percutaneous coronary interventions

Chronic coronary syndrome

- PCI or pills
- Deciding pro or contra PCI: Fractional Flow Reserve (FFR)
- Stent or drug coated balloon
- When to think hybrid

Acute coronary syndrome


Cardiogenic shock: still a major challenge



VS.



Ischemia & Prognosis



Hachamovitch et al. Circulation. 2003; 107:2900-2907





Figure 2. Percent of Patients Who Were Free of Angina Each Month after Randomization.

B Extended Follow-up Study Cohort



Sedlis et al. NEJM 2015 Courage Trial

ORBITA-Study

Enrolment assessment

Demographics
CCS
Questionnaires
Blood pressure, heart rate


Medical optimisation phase

6 weeks

Pre-randomisation assessment

CCS

Questionnaires
CPET
DSE
Blood pressure, heart rate



Follow-up assessment


CCS

Questionnaires CPET

DSE

Blood pressure, heart rate


ORBITA trial



Stenosis severity

	PCI n = 105	Placebo n = 95	Р
Area stenosis by QCA (%)	84.6 (SD 10.2)	84.2 (SD 10.3)	0.781
FFR	0.69 (SD 0.16)	0.69 (SD 0.16)	0.778
iFR	0.76 (SD 0.22)	0.76 (SD 0.21)	0.751

Primary endpoint result Change in total exercise time




Secondary endpoint results

Blinded evaluation of ischaemia reduction

Peak stress wall motion index score	PCI n = 80	Placebo n = 57	
Pre-randomization	1.11 (0.18)	1.11 (0.18)	
Follow-up	1.03 (0.06)	1.13 (0.19)	
Δ (Pre-randomization to follow-up)	-0.08 (0.17)	0.02 (0.16)	
	p<0.0001	p=0.433	
Difference in Δ between arms	-0.09 (-0.15 to -0.04) p=0.0011		

Secondary endpoint results CCS class improved in both groups





Chronic coronary syndrome: PCI or pills?


- PCI is not always the best choice
 - Various studies failed to demonstrate a prognostic benefit
 - COURAGE, ORBITA, ISCHEMIA . . .
- Good medical therapy is crucial


PCI for "uncontrollable" symptoms & for relevant ischemia

















The effect of OPN NC balloon













Coronary artery disease has many faces








Use of FFR and RFR for guidance


59 years old gentleman with diabetes


Atypical angina
 pathologic exercise testing


Coronary angiography
 — moderate LAD disease




LAD diffusely diseased ...












Wolverine 2.5 mm @ 24 atm






Wolverine 3.0 mm @ 24 atm OPN 3.0 @ 24 atm Selution 3.0 x 30 mm @ 4 atm









DCB in a CTO

60 years old man with Diabetes


Stable angina CCS 2


Coronary angiography → CTO of LCX





Coronary angiography 18 months later





Vascular Healing after IVL+DCB




NSTEMI, Wellens-ECG Pre (NSTEMI) 6 Months Follow up Post-Intervention Stent DEB

Calcification: Shockwave + DEB

Pre (NSTEMI) 6 Months Follow up Post-Intervention

Stent Edge (DEB), MLA 4.7mm2 -> 7.4mm2




Taking the best of two worlds: CABG & PCI

	CABG (conventional)	PCI
Invasiveness	+++	+
Prognosis	+++ (LIMA-LAD)	++
Patient Preference	+	+++
Recovery	+	+++




2 years post MIDCAB (Prof. Matt, LUKS)


OCT visualization of acute plaque rupture explaining recurrent ACS




83 years old lady with arterial hypertension and severe chest pain BP 70/30




STEMI patients are often complex ...






















Conclusions

 PCI has undergone a massive (r)evolution in the last 4 decades

In CCS: treat less, treat in a more targeted fashion

Combination of CABG & PCI is very promising

Use less stents & more drug coated balloons

Conclusions II

- In ACS: Use more intravascular imaging
- Cardiogenic shock: still a major challenge
- Impella could offer a good solution but randomized data badly needed